Brand/Development name: Folotyn
Company(ies): Allos Therapeutics
Principal Therapy Area: Cancer
Pralatrexate injection is a folate analogue metabolic inhibitor that competitively inhibits dihydrofolate reductase, a small enzyme that plays a supporting, but essential role, in the building of DNA and other processes. Pralatrexate is also a competitive inhibitor for polyglutamylation by the enzyme, folylpolyglutamyl synthetase. This inhibition results in the depletion of thymidine and other biological molecules, the synthesis of which depends on single carbon transfer.
Use this Cancer Drug Futures report to analyse key drivers and dampeners of success
An extensive review of the factors which can affect this product's clinical and commercial performance. Each drug report provides and covers…
What you get
A copy of the Cancer Drug Futures report(s) in print or pdf as you wish
Are you interested in more than one product, indication or therapy area?
Why not build a specific drug futures library and save money!
We appreciate that some customers will need to review many products. That is why, if you buy more than 5 Cancer Drug Futures reports of your choice, we can arrange
Customers focussing on specific disease areas can benefit from buying our cost-effective Cancer Drug Futures collections. Collections are available for the following cancer sectors:
For further information on the products covered, discounts, distribution or a demonstration, please click on the link for firstname.lastname@example.org